Infliximab exerts no direct hepatotoxic effect on HepG2 cells in vitro

11Citations
Citations of this article
31Readers
Mendeley users who have this article in their library.

Abstract

Background: Infliximab-induced hepatotoxicity is reported in several case studies involving patients with inflammatory bowel disease (IBD) and a direct hepatotoxic effect has been proposed. Objective: The aim of this study was to determine the direct in vitro toxicity of infliximab. As a proof of principle the in vitro toxicity of thiopurines and methotrexate was also determined. Methods: Cell survival curves and the half maximal inhibitory concentrations (IC50) were obtained after 24, 48 and 72 h of incubation in HepG2 cells with the IBD drugs azathioprine, 6-mercaptopurine, 6-thioguanine, methotrexate or infliximab by using the WST-1 cytotoxicity assay. Results: No in vitro hepatotoxicity in HepG2 cells was seen with infliximab, while concentration-dependent cytotoxicity was observed when HepG2 cells were incubated with increasing concentrations of azathioprine, 6-mercaptopurine and 6-thioguanine. Conclusion: Infliximab alone or given in combination with azathioprine showed no direct hepatotoxic effect in vitro, indicating that the postulated direct hepatotoxicity of infliximab is unlikely. © Springer Science+Business Media, LLC 2012.

Cite

CITATION STYLE

APA

De Vries, H. S., De Heij, T., Roelofs, H. M. J., Te Morsche, R. H. M., Peters, W. H. M., & De Jong, D. J. (2012). Infliximab exerts no direct hepatotoxic effect on HepG2 cells in vitro. Digestive Diseases and Sciences, 57(6), 1604–1608. https://doi.org/10.1007/s10620-012-2159-7

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free